Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology-oncology co-management.

HemaSphere·2026

Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026

Same author

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Neuro-oncology advances·2026

Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026

Same author

The prognostic significance of TSPO-PET imaging in IDH-mutant glioma: a single-center, retrospective study.

European journal of nuclear medicine and molecular imaging·2026

Same author

NeurAnki: Behind the Scenes of Creating the First-Ever Flashcard Based Deck for Resident Education (P12-5.009).

Neurology·2026

Same journal

Inferring DNA Methylation Class from Digitized Pathology Images and AI: A Worthy and Timely Application with Room for Improved Clinical Performance.

Neuro-oncology·2026

Same journal

The clinical and molecular landscape of thalamic glioma.

Neuro-oncology·2026

Same journal

MAPK-driven glioma progression and reprogramming of the tumor-associated immune response.

Neuro-oncology·2026

Same journal

Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline Glioma.

Neuro-oncology·2026

Same journal

Corrigendum to: Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Neuro-oncology·2026

Same journal

Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma.

Neuro-oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 9, 2025

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report.

Martin J van den Bent¹, Michael A Vogelbaum², Tim Cloughesy³

¹The Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

|May 3, 2025

Summary

This summary is machine-generated.

The Response Assessment in NeuroOncology (RANO) group standardizes neurooncology clinical trials through expert-led working groups and evidence-based guidelines. Their work improves trial design and response assessment for central nervous system tumors.

Keywords:

RANO brain metastases outcome criteria primary brain tumors

More Related Videos

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

Related Experiment Videos

Last Updated: May 9, 2025

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

Area of Science:

Neuro-oncology
Clinical Trial Design
Outcome Assessment

Background:

The Response Assessment in NeuroOncology (RANO) group was established to standardize clinical trials for central nervous system (CNS) tumors.
RANO addresses response assessment, trial design, and procedures to enhance neurooncology research.

Purpose of the Study:

To provide guidance and standardize clinical trial practices in neuro-oncology.
To foster collaboration and rapid response to advancements through expert-driven working groups.
To develop evidence-based guidelines and consensus recommendations for CNS tumor trials.

Main Methods:

Initiation of diverse working groups focused on various aspects of clinical trial design and outcome assessment.
Leveraging expertise without a rigid structure to ensure agility and responsiveness.
Convening recognized international experts to provide consensus-based guidance in the absence of definitive evidence.

Main Results:

Over 15 years, RANO has published more than 60 papers, many in high-impact journals.
RANO recommendations are accepted by regulatory bodies and industry as guiding principles.
Regular meetings, open to all, facilitate collaboration and the integration of new initiatives.

Conclusions:

RANO has significantly contributed to the standardization and improvement of neuro-oncology clinical trials.
The group's flexible, expert-driven approach facilitates adaptation to new developments.
RANO continues to welcome new initiatives and collaborations to advance CNS tumor research.